{
    "clinical_study": {
        "@rank": "43481", 
        "arm_group": [
            {
                "arm_group_label": "Florbetapir +ve NPH patients", 
                "arm_group_type": "Other", 
                "description": "Florbetapir +ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months"
            }, 
            {
                "arm_group_label": "Florbetapir -ve patients", 
                "arm_group_type": "Other", 
                "description": "Florbetapir -ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months"
            }
        ], 
        "brief_summary": {
            "textblock": "In this pilot study the investigators shall prospectively in a blinded fashion evaluate with\n      A\u03b2 PET and CSF A\u03b242 and tTau or pTau in patients committed to shunt surgery and then\n      investigate the relationship of these biomarkers with outcome on gait, cognition and urinary\n      control improvement in the short term (3 months) and long term (1 year). The imaging agent\n      will be provided by AVID.\n\n      Furthermore the study will standardize imaging studies using florbetapir F 18 PET to provide\n      information on amyloid burden."
        }, 
        "brief_title": "Prognostic Value of A\u03b2 Imaging in NPH Prior to Shunt Placement", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Normal Pressure Hydrocephalus Patients", 
        "condition_browse": {
            "mesh_term": [
                "Hydrocephalus", 
                "Hydrocephalus, Normal Pressure"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u2265 60.\n\n          2. Visual and auditory acuity adequate for neuropsychological testing.\n\n          3. Completed six grades of education or has a good work history (sufficient to exclude\n             mental retardation).\n\n          4. Must speak English fluently.\n\n          5. Willing to undergo one Amyloid imaging PET scan.\n\n          6. Agrees to at least one lumbar puncture for the collection of CSF.\n\n          7. Must agree to return for a Month 3 and Month 12 visit.\n\n          8. Participant, who in the opinion of the investigator, can tolerate the PET scan\n             procedures\n\n        Exclusion Criteria:\n\n          1. History of schizophrenia (DSM IV criteria).\n\n          2. History of alcohol or substance abuse or dependence within the past 2 years (DSM IV\n             criteria).\n\n          3. Participation in clinical studies involving neuropsychological measures being\n             collected more than one time per year.\n\n          4. Exclusion for amyloid imaging with 18F -AV-45: Current or recent participation in any\n             procedures involving radioactive agents such that the total radiation dose exposure\n             to the participant in any given year would exceed the limits of annual and total dose\n             commitment set forth in the US Code of Federal Regulations (CFR) Title 21 Section\n             361.1.\n\n          5. Clinically significant hepatic, renal, pulmonary, metabolic, or endocrine\n             disturbances as indicated by history, which in the opinion of the investigator might\n             pose a potential safety risk to the participant?\n\n          6. Current clinically significant cardiovascular disease, including one or more of:\n\n               -  cardiac surgery or myocardial infarction within the last 4 weeks;\n\n               -  unstable angina;\n\n               -  acute decompensated congestive heart failure or class IV heart failure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01834625", 
            "org_study_id": "11-004532"
        }, 
        "intervention": {
            "arm_group_label": [
                "Florbetapir +ve NPH patients", 
                "Florbetapir -ve patients"
            ], 
            "intervention_name": "Shunt surgery", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 5, 2014", 
        "location": {
            "contact": {
                "last_name": "Rita Fletcher, RN", 
                "phone": "904-453-7103"
            }, 
            "facility": {
                "address": {
                    "city": "Jacksonville", 
                    "country": "United States", 
                    "state": "Florida"
                }, 
                "name": "Mayo Clinic"
            }, 
            "investigator": {
                "last_name": "Neill r Graff-Radford, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prognostic Value of A\u03b2 Imaging in NPH Prior to Shunt Placement", 
        "overall_contact": {
            "last_name": "Rita Fletcher, RN", 
            "phone": "904-953-7103"
        }, 
        "overall_contact_backup": {
            "last_name": "Catherine Ruiz", 
            "phone": "904-953-6523"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Comparison of change between florbetapir +ve and -ve patients from baseline to one year in the Montreal Cognitive Assessment (MoCA)", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01834625"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Neill R. Graff-Radford, M.D.", 
            "investigator_title": "Professor of Neurology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}